Q2 2025 EPS Estimates for Applied Therapeutics, Inc. (NASDAQ:APLT) Increased by Analyst

Applied Therapeutics, Inc. (NASDAQ:APLT) – Analysts at Leerink Partnrs boosted their Q2 2025 EPS estimates for Applied Therapeutics in a note issued to investors on Wednesday, September 18th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of ($0.14) for the quarter, up from their previous forecast of ($0.15). The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.48) per share. Leerink Partnrs also issued estimates for Applied Therapeutics’ Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.36) EPS and FY2026 earnings at ($0.25) EPS.

Applied Therapeutics (NASDAQ:APLT) last issued its earnings results on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.03). The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $10.00 million.

APLT has been the subject of several other reports. William Blair upgraded shares of Applied Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Citigroup boosted their target price on Applied Therapeutics from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. Leerink Partners lifted their price target on Applied Therapeutics from $11.00 to $14.00 and gave the company an “outperform” rating in a report on Thursday, September 19th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $12.00 target price on shares of Applied Therapeutics in a research note on Wednesday, July 17th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Applied Therapeutics has an average rating of “Buy” and an average target price of $12.50.

Applied Therapeutics Trading Up 5.5 %

Shares of Applied Therapeutics stock opened at $8.11 on Monday. Applied Therapeutics has a 1 year low of $1.79 and a 1 year high of $9.39. The company has a market cap of $926.13 million, a P/E ratio of -4.40 and a beta of 2.03. The stock has a 50-day moving average price of $5.89 and a 200 day moving average price of $5.34.

Insider Activity at Applied Therapeutics

In other news, CEO Shoshana Shendelman sold 119,591 shares of Applied Therapeutics stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $5.93, for a total transaction of $709,174.63. Following the sale, the chief executive officer now directly owns 4,690,839 shares in the company, valued at approximately $27,816,675.27. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Applied Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Algert Global LLC bought a new stake in Applied Therapeutics during the 2nd quarter worth approximately $110,000. Frazier Life Sciences Management L.P. increased its holdings in shares of Applied Therapeutics by 17.1% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,286,135 shares of the company’s stock valued at $10,676,000 after purchasing an additional 333,278 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in Applied Therapeutics in the second quarter valued at about $172,000. Sei Investments Co. bought a new stake in Applied Therapeutics during the 2nd quarter worth about $535,000. Finally, Victory Capital Management Inc. bought a new position in Applied Therapeutics in the second quarter valued at approximately $54,000. Institutional investors own 98.31% of the company’s stock.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.